Granite Investment Partners LLC increased its stake in Cerus Corp. (NASDAQ:CERS) by 6.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 249,621 shares of the company’s stock after buying an additional 14,445 shares during the period. Granite Investment Partners LLC owned 0.24% of Cerus Corp. worth $1,550,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in the company. Marathon Capital Management increased its position in Cerus Corp. by 61.9% in the second quarter. Marathon Capital Management now owns 17,000 shares of the company’s stock valued at $106,000 after buying an additional 6,500 shares during the last quarter. Joel Isaacson & Co. LLC increased its position in Cerus Corp. by 13.7% in the third quarter. Joel Isaacson & Co. LLC now owns 17,050 shares of the company’s stock valued at $106,000 after buying an additional 2,050 shares during the last quarter. Nuveen Fund Advisors LLC bought a new position in Cerus Corp. during the second quarter valued at $129,000. Meristem LLP bought a new position in Cerus Corp. during the third quarter valued at $155,000. Finally, AQR Capital Management LLC bought a new position in Cerus Corp. during the second quarter valued at $181,000. 68.36% of the stock is owned by institutional investors.

Institutional Ownership by Quarter for Cerus Corp. (NASDAQ:CERS)

Shares of Cerus Corp. (NASDAQ:CERS) traded down 0.37% on Tuesday, reaching $5.45. The company had a trading volume of 358,039 shares. The company has a 50 day moving average price of $5.32 and a 200 day moving average price of $6.02. Cerus Corp. has a 52-week low of $4.22 and a 52-week high of $7.64. The stock’s market capitalization is $563.89 million.

Cerus Corp. (NASDAQ:CERS) last released its earnings results on Thursday, November 3rd. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.03. The firm earned $10.20 million during the quarter, compared to the consensus estimate of $10.34 million. Cerus Corp. had a negative return on equity of 76.76% and a negative net margin of 174.76%. The firm’s revenue for the quarter was up 27.5% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.17) earnings per share. On average, equities research analysts anticipate that Cerus Corp. will post ($0.64) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This report was reported by Daily Political and is the sole property of of Daily Political. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The original version of this report can be read at http://www.dailypolitical.com/2016/11/29/granite-investment-partners-llc-buys-14445-shares-of-cerus-corp-cers.html.

Several equities research analysts have recently issued reports on CERS shares. Robert W. Baird set a $10.00 price objective on Cerus Corp. and gave the stock a “buy” rating in a report on Saturday, August 6th. Cantor Fitzgerald set a $9.00 price objective on Cerus Corp. and gave the stock a “buy” rating in a report on Sunday, November 6th. FBR & Co restated a “buy” rating and set a $10.00 price objective on shares of Cerus Corp. in a report on Monday, November 7th. Zacks Investment Research upgraded Cerus Corp. from a “sell” rating to a “hold” rating in a report on Wednesday, November 2nd. Finally, BTIG Research restated a “buy” rating and set a $10.00 price objective on shares of Cerus Corp. in a report on Thursday, October 27th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. Cerus Corp. presently has an average rating of “Buy” and an average target price of $9.10.

About Cerus Corp.

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

5 Day Chart for NASDAQ:CERS

Want to see what other hedge funds are holding CERS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cerus Corp. (NASDAQ:CERS).

Receive News & Ratings for Cerus Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus Corp. and related companies with MarketBeat.com's FREE daily email newsletter.